Recorded a securities valuation loss of JPY 2,457 million due to decline in market value of investment securities in the first quarter of the fiscal year ending September 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4554","jir_company_name":"Fuji Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-02-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4554-20260205-02.pdf","jir_short_summary":"Recorded a securities valuation loss of JPY 2,457 million due to decline in market value of investment securities in the first quarter of the fiscal year ending September 2026.","jir_summary":"### Overview of Securities Valuation Loss\nIn the first quarter of the fiscal year ending September 2026 (October 1, 2025 to December 31, 2025), Fuji Pharmaceutical Co., Ltd. recorded a securities valuation loss of JPY 2,457 million due to a significant decline in the market value of other securities held by the company. The primary cause was a drop in the share price of Alvotech Holding S.A. (listed on NASDAQ), a global licensor in the biosimilar business. The valuation method used is the wash sale method; therefore, the valuation loss may fluctuate depending on stock prices at future quarterly and fiscal year-ends.\n\n### Outlook\nRegarding the impact on consolidated earnings for the cumulative second quarter and the full fiscal year ending September 2026, please refer to the 'Notice of Revision of Earnings Forecast' published on the same day. The fiscal year-end is September 30.","jir_financial_highlights":"Securities Valuation Loss: JPY 2,457 million (unknown)","jir_category":"","jir_hashtags":"#FujiPharmaceutical, #financial_summary, #securities_valuation_loss","jir_key_figures":"Securities Valuation Loss: JPY 2,457 million (First quarter of fiscal year ending September 2026)\nValued Stock: Alvotech Holding S.A. (listed on NASDAQ)\nFiscal Year-End: September 30","jir_meta_title":"Fuji Pharmaceutical Records JPY 2,457 Million Securities Valuation Loss in Q1 FY2026","jir_meta_description":"Fuji Pharmaceutical recorded a valuation loss of JPY 2,457 million in Q1 FY2026 due to a decline in investment securities prices, mainly impacted by NASDAQ-listed Alvotech shares. Attention is focused on the revision of earnings forecasts.","jir_og_title":"Fuji Pharmaceutical Posts JPY 2,457 Million Securities Valuation Loss in Q1 FY2026","jir_og_description":"Due to a drop in NASDAQ-listed Alvotech stock price, Fuji Pharmaceutical recorded a securities valuation loss in Q1 FY2026. For details, see the earnings forecast revision.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17504,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-24826","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n